JAK Inhibitors Show Limited Efficacy in Refractory JIA Uveitis

This small retrospective cohort tempers early case-report enthusiasm, showing that oral Janus kinase inhibitors achieve only transient ocular quiescence and modest steroid sparing in heavily pretreated pediatric uveitis.

tofacitinibbaricitinibupadacitinibJAK inhibitorsjuvenile idiopathic arthritisuveitisJIAUDMARDpediatric rheumatologyretrospective cohortadalimumab Rheumatology / Immunology

Background Information

Janus kinase inhibitors show limited efficacy in JIA-associated uveitis.

Children with juvenile idiopathic arthritis-associated uveitis (JIAU) often face chronic inflammation and limited treatment options. Janus kinase inhibitors (JAKi) showed limited success, with only 8 out of 20 patients achieving uveitis inactivity, and relapses occurring in 6 of them. The study highlights limited efficacy of JAKi in treating drug-resistant JIAU, stressing the need for alternative therapies despite some steroid sparing. JAK inhibitors may not be effective for chronic DMARD-refractory JIAU.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Baquet-Walscheid K, Wortmann C, Rothaus K, Ohlmeier C, Heinz C, Windschall D, Heiligenhaus A

Citation: Baquet-Walscheid K, Wortmann C, Rothaus K, et al. Janus kinase inhibitors are of limited use in refractory JIA-associated uveitis: retrospective data from a tertiary uveitis center. Pediatric rheumatology online journal. 2026. doi:10.1186/s12969-026-01243-2

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →